|Articles|March 1, 2001

March 2001
Volume 7
Issue 3

Renal Effects of Angiotensin-Converting Enzyme Inhibitors That Result in Cost Savings and Improved Patient Outcomes

Author(s)Arthur L. M. Swislocki, MD, David Siegel, MD, MPH

Download PDF: Renal Effects of Angiotensin-Converting Enzyme Inhibitors That Result in Cost Savings and Improved Patient Outcomes

Articles in this issue

almost 25 years ago

Article

Prior-Authorization Requirements for Patient Referrals to Specialists

almost 25 years ago

Article

Assessing Safety of New Technology: Conference Looks at Evaluation Process

almost 25 years ago

Article

Physician Perceptions of a National Formulary

almost 25 years ago

Article

Specialty of Principal Care Physician and Medicare Expenditures in Patients with Coronary Artery Disease:Impact of Comorbidity and Severity

almost 25 years ago

Article

Clinical and Economic Outcomes of an Ambulatory Urinary Tract Infection Disease Management Program

almost 25 years ago

Article

Are Patients' Chief Complaints Generally Specific to One Organ System?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

ByNate C. Apathy, PhD

January 27th 2026

Building Trust: Public Priorities for Health Care AI Labeling

ByMorgan L. Sielaff, BS,Jodyn Platt, PhD, MPH,Sean Tan, MPP,Kerry A. Ryan, MA,Paige Nong, PhD,Sharon L. R. Kardia, PhD

January 27th 2026

Ambient AI Tool Adoption in US Hospitals and Associated Factors

ByFreddie Yang, MA,Ilana Graetz, PhD

January 27th 2026

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

ByTaylor I. Bucy, PhD,John P. McHugh, PhD,Dori A. Cross, PhD

January 26th 2026

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Renal Effects of Angiotensin-Converting Enzyme Inhibitors That Result in Cost Savings and Improved Patient Outcomes

Articles in this issue

Newsletter

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

Specialty and Operator Status Influence Electronic Health Record Use Variation

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule

AI-Supported Mammography Caught More Cancers During Screening

Combination Therapy, Biologics, and Surgery Redefine HS Care in 2026

CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment

Treatment for Glaucoma Continues to Evolve, Allowing Eye Doctors to Personalize Treatment: Manjool Shah, MD